+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

Advances in Experimental Medicine and Biology 397: 7-13

Three model systems were used to demonstrate the immunogenicity of highly attenuated and replication-defective recombinant MVA. (1) Intramuscular inoculation of MVA-IN-Fha/np induced humoral and cell-mediated immune responses in mice and protectively immunized them against a lethal respiratory challenge with influenza virus. Intranasal vaccination was also protective, although higher doses were needed. (2) In rhesus macaques, an immunization scheme involving intramuscular injections of MVA-SIVenv/gag/pol greatly reduced the severity of disease caused by an SIV challenge. (3) In a murine cancer model, immunization with MVA-beta gal prevented the establishment of tumor metastases and even prolonged life in animals with established tumors. These results, together with previous data on the safety of MVA in humans, suggest the potential usefulness of recombinant MVA for prophylactic vaccination and therapeutic treatment of infectious diseases and cancer.

(PDF emailed within 1 workday: $29.90)

Accession: 046274889

Download citation: RISBibTeXText

PMID: 8718576

Related references

Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development. Developments in Biological Standardization 82: 55-63, 1994

Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Developments in Biological Standardization 84: 195-200, 1995

Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. Vaccine 2019, 2019

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 12(11): 1032-1040, 1994

A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 190(1): 454-458, 1992

Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells. Acta Virologica 45(4): 243-247, 2002

Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proceedings of the National Academy of Sciences of the United States of America 104(23): 9788-9793, 2007

Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology 335(2): 242-251, 2005

A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. Virology 507: 242-256, 2017

Transient dominant host-range selection using Chinese hamster ovary cells to generate marker-free recombinant viral vectors from vaccinia virus. Biotechniques 62(4): 183-187, 2017

Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. Journal of Virology 68(7): 4109-4116, 1994

Immunogenicity analysis of HIV vaccine based on replicating vaccinia virus Tiantan vector. Zhonghua Shi Yan He Lin Chuang Bing du Xue Za Zhi 18(3): 281-283, 2005

Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys. Journal of Virology 87(10): 5669-5677, 2013

Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors. Plos One 8(10): E76344, 2014

Optimization of production procedure of replicating recombinant live vaccinia virus vector-based vaccine. Chinese Journal of Biologicals 21(2): 131-132,138, 2008